The reason for developing agents comprising a bombesin-derived agent (targeting the GRPR) and a Glu-urea-Lys or Glu-urea-Glu structure motive (addressing the PSMA) for imaging of prostate carcinoma (PCa) results from the changes of the receptor statuses during progression of the disease. Here, FOLH1 is linked to prostate carcinoma.